About relmada therapeutics inc - RLMD
Relmada Therapeutics, Inc. engages in the development of clinical-stage drugs. The firm's pipeline includes NDV-01 and Sepranolone. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
RLMD At a Glance
Relmada Therapeutics, Inc.
2222 Ponce de Leon Boulevard
Coral Gables, Florida 33134
| Phone | 1-786-629-1376 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -57,385,163.00 | |
| Sector | Health Technology | Employees | 17 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
RLMD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.094 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.653 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
RLMD Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,375,597.824 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
RLMD Liquidity
| Current Ratio | 14.615 |
| Quick Ratio | 14.615 |
| Cash Ratio | 14.463 |
RLMD Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -82.084 |
| Return on Equity | -94.048 |
| Return on Total Capital | -66.332 |
| Return on Invested Capital | -94.048 |
RLMD Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |